Home > Medical Affairs > Experienced Medical Leadership

Experienced Medical Leadership

Abraxis Oncology Medical Affairs plays an integral role in the support of oncology product development by supporting investigator-sponsored research, and disseminating and communicating data from clinical trials via scientific publications. Medical Affairs delivers accurate and balanced medical information to healthcare professionals who seek to learn more about Abraxis Oncology’s products and proprietary nab™ Technology platform. Abraxis Oncology contributes to healthcare professional education through its sponsorship of medical educational programs. The group also plays a key role in establishing and maintaining relationships with key scientific leaders. Information about clinical trials, the medical grants process, and publications, as well as other helpful resources, can be found in this section.

04/15/08 - Abraxis BioScience Presents New Preclinical Data Demonstrating Eradication of Large Orthotopic Breast Tumors and Metastasis with Combined nab-Paclitaxel (ABRAXANE(R)) and Bevacizumab (Avastin(R)) Therapy
04/09/08 - Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
04/04/07 - Abraxis BioScience Acquires Shimoda Biotech and Platco Technologies

Abraxis Oncology is a division of Abraxis BioScience, LLC. AO 997/268353 August 2008
All Abraxis BioScience, LLC corporate names (eg, ABRAXIS, ABRAXIS ONCOLOGY, ABRAXIS BIOSCIENCE, and their logos), names of services, and names of products (eg, ABRAXANE^® and the ABRAXANE logo) referred to herein are trade names, service marks and/or trademarks that are owned by or licensed to Abraxis BioScience, its divisions, or its affiliates, unless otherwise noted.